Caris Life Sciences, Inc. (CAI) Revenue by Segment & Business Profile
Molecular Profiling Services was 95.7% of Caris Life Sciences, Inc.'s revenue across the 2 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CAICaris Life Sciences, Inc.Follow CAI — free
—
Price chart with a free account
- Market cap
- 9.0B
- P/E TTM
- 85.6
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What the company does
Caris Life Sciences, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Molecular Profiling Services (96%), Pharma Research And Development Services (4%). Trailing twelve-month revenue: $989.6 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Platform (mRNA / RNAi / gene)
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 262M | 99.2% | +46.8% |
| Outside the US | 2M | 0.8% | -33.6% |
Caris Life Sciences, Inc. — questions
- What does Caris Life Sciences, Inc. do?
- Caris Life Sciences, Inc. is a biotechnology company in the healthcare sector. In its SEC filings it reports 2 business lines: Molecular Profiling Services (96%), Pharma Research And Development Services (4%). Trailing twelve-month revenue: $989.6 million as of 2026-06-30.
- How does Caris Life Sciences, Inc. make money?
- By the lines it reports in its SEC filings: Molecular Profiling Services 95.7%, Pharma Research And Development Services 4.3% of revenue.
Every figure on this page comes from Caris Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.